Edition:
India

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
13 Jul 2018
Change (% chg)

$0.01 (+0.78%)
Prev Close
$1.29
Open
$1.31
Day's High
$1.31
Day's Low
$1.26
Volume
9,143
Avg. Vol
135,916
52-wk High
$8.79
52-wk Low
$0.75

Latest Key Developments (Source: Significant Developments)

Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone Receptor-Positive Breast Cancer Patients
Monday, 7 May 2018 

May 7 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. ENTERS INTO AGREEMENT TO ACQUIRE PRODUCT TO ADDRESS VULVAR AND VAGINAL ATROPHY IN HORMONE RECEPTOR-POSITIVE BREAST CANCER PATIENTS.DARE BIOSCIENCE INC - DARÉ HAS ENTERED INTO AGREEMENT TO SECURE RIGHTS, CURRENTLY OWNED BY PEAR TREE, TO DEVELOP PT-101.  Full Article

Dare Bioscience Announces Development And Option Agreement With Orbis Biosciences For Long-Acting Injectable Contraceptive
Monday, 12 Mar 2018 

March 12 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE ANNOUNCES EXCLUSIVE DEVELOPMENT AND OPTION AGREEMENT WITH ORBIS BIOSCIENCES FOR LONG-ACTING INJECTABLE CONTRACEPTIVE.DARE BIOSCIENCE - AGREEMENT TERMS WITH ORBIS PROVIDE CO OPTION TO ENTER LICENSE AGREEMENT FOR ORB-204 & ORB-214 SHOULD DEVELOPMENT EFFORTS SUCCEED.  Full Article

Dare Bioscience Says Entered Into Common Stock Sales Agreement
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Dare Bioscience Inc ::DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING.DARE BIOSCIENCE - UNDER AGREEMENT, CO MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $10 MILLION.  Full Article

Cerulean Pharma says reducing workforce by about 48 pct
Friday, 19 Aug 2016 

Cerulean Pharma Inc : Cerulean announces reduction in force . Says reducing its workforce by about 48 pct, to a total of 23 full-time equivalent employees . Says expects reduction plan to be substantially completed by end of 2016 . Says workforce reduction is designed to reduce operating expenses while co refocuses its clinical strategy for CRLX101 .Expects reduction in force to result in about $5 million in reduced annualized operating expenses.  Full Article

Cerulean says has enough cash to fund planned ops into Q2 2017
Friday, 5 Aug 2016 

Cerulean Pharma Inc : Cerulean reports second quarter 2016 corporate highlights and financial results . Believes its cash and cash equivalents are sufficient to fund its planned operations into q2 of 2017 .Qtrly net loss attributable to stockholders for q2 was $10.9 million, compared to net loss attributable to common stockholders of $9.9 million.  Full Article

BRIEF-Daré Bioscience Appoints John Fair To Chief Business Officer

* DARÉ BIOSCIENCE, INC. EXPANDS LEADERSHIP TEAM, APPOINTING JOHN FAIR TO CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage: